SEC 13F Intelligence

Managers / Q2 2022 · view latest →

SECTORAL ASSET MANAGEMENT INC

CIK 0001274413 · 1010 SHERBROOKE ST., WEST, SUITE 1610, MONTREAL, A8, H3A 2R7 · 514 849 8777

Reported Value
$496M
Q2 2022
Positions
112
Filings on Record
30
2019–present window
Filed
Aug 15, 2022
original filing

Summary

Sectoral Asset Management Inc reported $496M in U.S.-listed holdings across 112 positions for Q2 2022.

Its largest position, UNH, represents 3.7% of the portfolio.

Compared with Q1 2022, the fund opened 23 new positions and exited 17.

Portfolio Metrics

Turnover
+16.8%
vs prior filed quarter
Top-10 Concentration
+25.4%
share of reported value
Largest Position
+3.7%
Unitedhealth
New / Exited
23 / 17
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $736MQ4 ’18Q1 ’19: $831MQ2 ’19: $836MQ3 ’19: $580MQ4 ’19: $670MQ4 ’19Q1 ’20: $521MQ2 ’20: $1.1BQ3 ’20: $1.2BQ4 ’20: $1.4BQ4 ’20Q1 ’21: $1.3BQ2 ’21: $1.2BQ3 ’21: $1.2BQ4 ’21: $664MQ4 ’21Q1 ’22: $563MQ2 ’22: $496MQ3 ’22: $508MQ4 ’22: $517MQ4 ’22Q1 ’23: $520MQ2 ’23: $600MQ3 ’23: $514MQ4 ’23: $232MQ4 ’23Q1 ’24: $254MQ2 ’24: $246MQ3 ’24: $169MQ4 ’24: $150MQ4 ’24Q1 ’25: $128MQ2 ’25: $151MQ3 ’25: $162MQ4 ’25: $125MQ4 ’25Q1 ’26: $121Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 84.5%Other: 14.0%ADR: 1.5%
  • Common Stock · 84.5% · $419M
  • Other · 14.0% · $70M
  • ADR · 1.5% · $7M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2022 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
R1 RCM INCNEW+604.0K604.0K+$13M$13M
LNTHLANTHEUS HLDGS INCNEW+88.7K88.7K+$6M$6M
ALKERMES PLCNEW+189.7K189.7K+$6M$6M
TVTXTRAVERE THERAPEUTICSNEW+232.0K232.0K+$6M$6M
ITCIEURINTRA CELLULAR THERANEW+90.8K90.8K+$5M$5M
PROMETHEUS BIOSCIENCNEW+172.5K172.5K+$5M$5M
IQVIQVIA HOLDINGS INCNEW+16.0K16.0K+$3M$3M
KARUNA THERAPEUTICSNEW+24.0K24.0K+$3M$3M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2022

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1UNHUNITEDHEALTH GRP INChistory →COM3.72%$18M35.9K
2HQYHEALTHEQUITY INChistory →COM2.98%$15M240.6K
3R1 RCM INCCOM2.55%$13M604.0K
4INARI MED INCCOM2.52%$12M183.8K
5JNJJOHNSON & JOHNSONhistory →COM2.43%$12M67.8K
6BMRNBIOMARIN PHARMAC INChistory →COM2.37%$12M141.7K
7EVHEVOLENT HEALTH INChistory →COM2.30%$11M372.1K
8ARVNARVINAS INChistory →COM2.26%$11M267.0K
98INSYNEOS HEALTH INChistory →CL A2.21%$11M152.7K
10IM8NINSMED INChistory →COM2.05%$10M515.5K
11PTCTPTC THERAPEUTICS Ihistory →COM1.94%$10M239.9K
12INSPINSPIRE MED SYS INChistory →COM1.90%$9M51.6K
13ATRCATRICURE INChistory →COM1.88%$9M228.5K
14BIOHAVEN PHARMACTLCOM1.85%$9M63.1K
15AGILITI INCCOM1.83%$9M443.2K
16PRVAPRIVIA HEALTH GROUPhistory →COM1.74%$9M297.2K
17SILKUSDSILK ROAD MEDICALhistory →COM1.66%$8M226.8K
18IRTCIRHYTHM TECHNOLOGIEShistory →COM1.63%$8M75.0K
19EX9EXELIXIS INChistory →COM1.61%$8M383.0K
20RCUSARCUS BIOSCIENCEShistory →COM1.59%$8M311.8K
21ICON PLCSHS1.57%$8M35.9K
22APLSUSDAPELLIS PHARMACEUTIChistory →COM1.40%$7M153.3K
23PFEPFIZER INChistory →COM1.37%$7M129.4K
24TURNING POINT THERAPCOM1.36%$7M90.0K
25AXNX*AXONICS INChistory →COM1.35%$7M118.7K
26HUMHUMANA INChistory →COM1.34%$7M14.2K
27TNDMTANDEM DIABETES CAREhistory →COM1.26%$6M105.8K
28ABBVABBVIE INChistory →COM1.24%$6M40.3K
29ABTABBOTT LABShistory →COM1.24%$6M56.7K
30AM6AMICUS THERAPEUTICShistory →COM1.21%$6M560.9K
31LLYLILLY ELI & COhistory →COM1.20%$6M18.4K
32DNLIDENALI THERAPEUTICShistory →COM1.20%$6M202.1K
33SWAVUSDSHOCKWAVE MEDICALhistory →COM1.19%$6M31.0K
34LNTHLANTHEUS HLDGS INChistory →COM1.18%$6M88.7K
35SGENUSDSEAGEN INChistory →COM1.16%$6M32.5K
36HALOHALOZYME THERAPEUTIChistory →COM1.16%$6M130.4K
37ALKERMES PLCSHS1.14%$6M189.7K
38TVTXTRAVERE THERAPEUTICShistory →COM1.13%$6M232.0K
39TMCITREACE MED CONCEPThistory →COM1.09%$5M376.7K
40THCTENET HEALTHCAREhistory →COM1.07%$5M101.5K
41MRKMERCK & CO INChistory →COM1.06%$5M57.8K
42ITCIEURINTRA CELLULAR THERAhistory →COM1.04%$5M90.8K
43PROMETHEUS BIOSCIENCCOM0.98%$5M172.5K
44BSXBOSTON SCIENTIFICCOM0.95%$5M127.0K
45BLUBELLUS HEALTH INCCOM NEW0.93%$5M501.4K
46MRTXEURMIRATI THERAPEUTICSCOM0.93%$5M68.6K
47FATEFATE THERAPEUTICSCOM0.91%$5M183.0K
48STAASTAAR SURGICAL COCOM0.89%$4M62.5K
49IMGNEURIMMUNOGEN INCCOM0.85%$4M940.2K
50CONVEY HEALTH SOL HLCOM0.84%$4M400.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$121M77May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$125M74Feb 9, 202613F-HRchanges · EDGAR ↗
Q3 2025$162M82Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$151M94Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$128M84May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$150M86Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$169M90Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$246M97Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$254M92May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$232M104Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$514M123Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$600M121Aug 11, 202313F-HRchanges · EDGAR ↗
Q1 2023$520M118May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022$517M120Feb 10, 202313F-HRchanges · EDGAR ↗
Q3 2022$508M109Nov 10, 202213F-HRchanges · EDGAR ↗
Q2 2022$496M112Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$563M106May 10, 202213F-HRchanges · EDGAR ↗
Q4 2021$664M108Feb 11, 202213F-HRchanges · EDGAR ↗
Q3 2021$1.2B127Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$1.2B127Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$1.3B113May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.4B97Feb 12, 202113F-HRchanges · EDGAR ↗
Q3 2020$1.2B88Nov 13, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.1B191Aug 13, 202013F-HRchanges · EDGAR ↗
Q1 2020$521M65May 13, 202013F-HRchanges · EDGAR ↗
Q4 2019$670M65Feb 12, 202013F-HRchanges · EDGAR ↗
Q3 2019$580M63Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$836M92Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$831M106May 14, 201913F-HRchanges · EDGAR ↗
Q4 2018$736M104Feb 12, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.